Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

Lilly closes on US approval of lung cancer drug necitumumab

Lilly closes on US approval of lung cancer drug necitumumab Other drugs targeting EGFR are already on the market for NSCLC, including orally-active therapies such as Roche's Tarceva (erlotinib), AstraZeneca's Iressa (gefitinib) and Boehringer Ingelheim's Giotrif (afatinib). ... Boehringer has just reported phase

Boehringer plans new filings for Giotrif in lung cancer

Boehringer plans new filings for Giotrif in lung cancer The German pharma company reports that Giotrif (afatinib) was more effective than Roche's Tarceva (erlotinib) in extending the lives of previously treated SCC patients in the study, which has just ... In addition to Tarceva it also competes with Iressa

Opdivo approved via UK’s early drug access scheme

Opdivo approved via UK’s early drug access scheme Alimta (pemetrexed), and Roche's Tarceva (erlotinib) – all of which have seen positive NICE recommendations. .

NICE U-Turn on Boehringer oncology drug

NICE U-Turn on Boehringer oncology drug There are a number of NICE-approved medicines for NSCLC, including AstraZeneca's Iressa (gefitinib) and Roche's Tarceva (erlotinib), which are both targeted EGFR mutation positive treatments. .

Express Scripts pushes for pay-for-performance in cancer

Express Scripts pushes for pay-for-performance in cancer He gives the example of Roche and Astellas' Tarceva (erlotinib), which is less effective in pancreatic cancer than in lung cancer.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics